Haukeland University Hospital

Aclarion’s Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain

Retrieved on: 
Thursday, April 25, 2024
CO, Pain, ACON, Randomized controlled trial, Oslo University Hospital, Haukeland University Hospital, Software as a service, Low back pain, Biomarker, Patient, Physician, Diagnosis, Clinical trial, Algorithm, Akershus University Hospital

BROOMFIELD, CO, April 25, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that the Nociscan solution will be utilized in the upcoming LIFEHAB Trial in Norway. The randomized controlled trial studying 202 patients with low back pain greater than 1 year in duration will compare treatment outcomes between lumbar interbody fusion surgery and multidisciplinary rehabilitation.

Key Points: 
  • “Diagnosing the source of chronic low back pain is  a significant challenge for clinicians,” said Dr. Ansgar Espeland.
  • “At Haukeland University Hospital, our radiology team has participated in numerous clinical trials seeking to better understand the linkage between the diagnosis and treatment of chronic low back pain.
  • The LIFEHAB Trial is our latest effort to advance scientific understanding of chronic low back pain.
  • The LIFEHAB trial represents the fourth important trial since 2021 to utilize Nociscan, a testament to our growing body of evidence and the relative distinction of the Nociscan solution.”
    For more information on the LIFEHAB Trial: https://classic.clinicaltrials.gov/ct2/show/NCT06169488

Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro

Retrieved on: 
Wednesday, February 21, 2024
Nobel Prize, Bial, University of Glasgow, Messenger, Synapse, Teaching hospital, Glioblastoma, Neuron, Neoplasm, Thought, University Hospital Heidelberg, University of Bergen, Vaccine, University, Haukeland University Hospital, COVID-19, Memory, Glioma, Jury, Heidelberg University, University Hospital Mannheim, Brain, Epilepsy, Tissue, Research, German Cancer Research Center, Medical imaging

This is possible by formation of synapses between neurons and cancer cells.

Key Points: 
  • This is possible by formation of synapses between neurons and cancer cells.
  • This paper shows that cancer cells cannot merely proliferate - they have to hijack healthy biological processes and integrate themselves into the normal function of tissues.
  • "Nowhere is this more blatant - and surprising - than in the brain tumours studied in this paper", says Ralph Adolphs.
  • The award-winning research also provides a new explanation for why epilepsy and tumour progression are often observed together: epilepsy may be a cause, rather than a consequence of the tumour progression.

Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro

Retrieved on: 
Wednesday, February 21, 2024
Nobel Prize, Bial, University of Glasgow, Messenger, Synapse, Teaching hospital, Glioblastoma, Neuron, Neoplasm, Thought, University Hospital Heidelberg, University of Bergen, Vaccine, University, Haukeland University Hospital, COVID-19, Memory, Glioma, Jury, Heidelberg University, University Hospital Mannheim, Brain, Epilepsy, Tissue, Research, German Cancer Research Center, Medical imaging

This is possible by formation of synapses between neurons and cancer cells.

Key Points: 
  • This is possible by formation of synapses between neurons and cancer cells.
  • This paper shows that cancer cells cannot merely proliferate - they have to hijack healthy biological processes and integrate themselves into the normal function of tissues.
  • "Nowhere is this more blatant - and surprising - than in the brain tumours studied in this paper", says Ralph Adolphs.
  • The award-winning research also provides a new explanation for why epilepsy and tumour progression are often observed together: epilepsy may be a cause, rather than a consequence of the tumour progression.

A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)

Retrieved on: 
Thursday, November 30, 2023
Health, Neurology, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Brain, Safety, Research, Deficit spending, Parkinson's disease, Cell Metabolism, ChromaDex, Disease, Tremor, Stiffness, Nicotinamide adenine dinucleotide, Neuron, Nature Communications, Agonal respiration, Dementia, University, Person, Mitochondrion, Translational research, Haukeland University Hospital, University of Bergen, NAD, Pharmaceutical industry, Medical device, PD

These results build upon previous research led by Dr. Tzoulis ( Cell Metabolism ) and showcase that supplementation with Niagen NR may be a therapeutic strategy for PD, pending further research.

Key Points: 
  • These results build upon previous research led by Dr. Tzoulis ( Cell Metabolism ) and showcase that supplementation with Niagen NR may be a therapeutic strategy for PD, pending further research.
  • Current treatment options are limited, and there is a pressing need for innovative approaches to manage the effects of this debilitating neurodegenerative disorder.
  • This study establishes the short-term safety of 3,000 mg NR daily and allows the clinical community to explore high-dose options in future therapeutic trials.
  • Notably, all of Prof. Tzoulis’ clinical research is academically-driven and based largely on public funding.

New Data on BerGenBio's Selective AXL Inhibitor Bemcentinib Released Today at 2023 ESMO Meeting

Retrieved on: 
Monday, October 23, 2023
OSE, Data analysis, ESMO, Publication, Pembrolizumab, Assistant professor, Non-small-cell lung cancer, STK11, Haukeland University Hospital, Melanoma, European Society for Medical Oncology, Patient, AXL, Pharmaceutical industry, Medical device, NSCLC

In addition, the combination of bemcentinib with pembrolizumab was well tolerated with no new safety signals identified.

Key Points: 
  • In addition, the combination of bemcentinib with pembrolizumab was well tolerated with no new safety signals identified.
  • These data provide a strong foundation for further clinical investigations of bemcentinib in NSCLC patients with high unmet needs, including those with STK11 mutations."
  • Dr. Oliva continued, "During the meeting, our collaborator, Dr. Oddbjorn Straume, also presented data on the combination of bemcentinib with standard of care therapies in first line and second line melanoma patients.
  • In totality, these new data substantiate BerGenBio's focused strategy on the treatment of first line NSCLC patients with STK11m patients in our on-going BGBC016 study."

New Data on BerGenBio's Selective AXL Inhibitor Bemcentinib Released Today at 2023 ESMO Meeting

Retrieved on: 
Monday, October 23, 2023
OSE, Data analysis, ESMO, Publication, Pembrolizumab, Assistant professor, Non-small-cell lung cancer, STK11, Haukeland University Hospital, Melanoma, European Society for Medical Oncology, Patient, AXL, Pharmaceutical industry, Medical device, NSCLC

In addition, the combination of bemcentinib with pembrolizumab was well tolerated with no new safety signals identified.

Key Points: 
  • In addition, the combination of bemcentinib with pembrolizumab was well tolerated with no new safety signals identified.
  • These data provide a strong foundation for further clinical investigations of bemcentinib in NSCLC patients with high unmet needs, including those with STK11 mutations."
  • Dr. Oliva continued, "During the meeting, our collaborator, Dr. Oddbjorn Straume, also presented data on the combination of bemcentinib with standard of care therapies in first line and second line melanoma patients.
  • In totality, these new data substantiate BerGenBio's focused strategy on the treatment of first line NSCLC patients with STK11m patients in our on-going BGBC016 study."

Additional data on BerGenBio's selective AXL inhibitor bemcentinib to be presented at the 2023 ESMO meeting

Retrieved on: 
Monday, October 16, 2023
AXL, Vall d'Hebron University Hospital, NSCLC, Trial of the century, Haukeland University Hospital, Lung cancer, Teaching hospital, OSE, ESMO, Vall, Assistant professor, Nursing, Patient, Poster, Pharmaceutical industry

BERGEN, Norway, Oct. 16, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster and an oral presentation summarizing completed studies with its lead product candidate bemcentinib will be presented at the upcoming European Society of Clinical Oncologists (ESMO) Annual Meeting 2023, to be held October 20-24 in Madrid.

Key Points: 
  • BERGEN, Norway, Oct. 16, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster and an oral presentation summarizing completed studies with its lead product candidate bemcentinib will be presented at the upcoming European Society of Clinical Oncologists (ESMO) Annual Meeting 2023, to be held October 20-24 in Madrid.
  • Enriqueta Felip, M.D., Ph.D., Head of the Thoracic Cancer Unit at Vall d'Hebron University Hospital, Spain will present the following poster summarizing the final results from the BGBC008 Phase II study of bemcentinib in combination with pembrolizumab in 2L NSCLC:
    Poster Title: Final top-line results of the BGBC008 phase 2, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in 2nd line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571) of S
    The poster will be available on BerGenBio's website shortly following presentation.
  • In addition, Dr.  Oddbjorn Straume, M.D., Ph.D., Assistant Professor, Clinical Science at the Haukeland University Hospital in Bergen, Norway will make an oral presentation summarizing the results of the Investigator Led Study LBA52 with bemcentinib in addition to pembrolizumab or dabrafenib/trametinib in 1L and 2L metastatic melanoma patients:
    Martin Olin, Chief Executive Officer of BerGenBio, commented: "We are pleased to share more data on bemcentinib which we believe substantiates our strategy to focus on the treatment of Non-Small Cell Lung Cancer patients with a goal of potentiating the effects of standard of care treatments.
  • We thank the patients who participated in these studies, their families, and all participating investigators as well as their clinical and nursing staff for contributing to our understanding of bemcentinib as a potential cancer therapeutic."

Additional data on BerGenBio's selective AXL inhibitor bemcentinib to be presented at the 2023 ESMO meeting

Retrieved on: 
Monday, October 16, 2023
AXL, Vall d'Hebron University Hospital, NSCLC, Trial of the century, Haukeland University Hospital, Lung cancer, Teaching hospital, OSE, ESMO, Vall, Assistant professor, Nursing, Patient, Poster, Pharmaceutical industry

BERGEN, Norway, Oct. 16, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster and an oral presentation summarizing completed studies with its lead product candidate bemcentinib will be presented at the upcoming European Society of Clinical Oncologists (ESMO) Annual Meeting 2023, to be held October 20-24 in Madrid.

Key Points: 
  • BERGEN, Norway, Oct. 16, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster and an oral presentation summarizing completed studies with its lead product candidate bemcentinib will be presented at the upcoming European Society of Clinical Oncologists (ESMO) Annual Meeting 2023, to be held October 20-24 in Madrid.
  • Enriqueta Felip, M.D., Ph.D., Head of the Thoracic Cancer Unit at Vall d'Hebron University Hospital, Spain will present the following poster summarizing the final results from the BGBC008 Phase II study of bemcentinib in combination with pembrolizumab in 2L NSCLC:
    Poster Title: Final top-line results of the BGBC008 phase 2, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in 2nd line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571) of S
    The poster will be available on BerGenBio's website shortly following presentation.
  • In addition, Dr.  Oddbjorn Straume, M.D., Ph.D., Assistant Professor, Clinical Science at the Haukeland University Hospital in Bergen, Norway will make an oral presentation summarizing the results of the Investigator Led Study LBA52 with bemcentinib in addition to pembrolizumab or dabrafenib/trametinib in 1L and 2L metastatic melanoma patients:
    Martin Olin, Chief Executive Officer of BerGenBio, commented: "We are pleased to share more data on bemcentinib which we believe substantiates our strategy to focus on the treatment of Non-Small Cell Lung Cancer patients with a goal of potentiating the effects of standard of care treatments.
  • We thank the patients who participated in these studies, their families, and all participating investigators as well as their clinical and nursing staff for contributing to our understanding of bemcentinib as a potential cancer therapeutic."

ChromaDex, a Global Authority on Nicotinamide Adenine Dinucleotide (NAD+), Celebrates the 10th Anniversary of its ChromaDex External Research Program (CERP™), the Industry Leading Research Program Advancing the Science of NAD+ and Healthy Aging

Retrieved on: 
Friday, June 16, 2023
Health, Hospitals, Other Health, General Health, Pharmaceutical, Vitamins, Supplements, Biotechnology, University of Helsinki, Science, Human, Cell Metabolism, University, PD, Heart failure, Metabolism, CERP, Science Advances, NR, Placebo, LVEF, Spinal cord, Research fellow, Clinical trial, Ageing, NAD, University of Oslo, Philip Morris External Research Program, ChromaDex, Research, Brain, Inflammation, Affiliation, Mitochondrion, DSM-IV codes, University of Washington School of Medicine, Trial of the century, Associate, Haukeland University Hospital, University of Bergen, City, Publication, Parkinson's disease, Patient, Division, Heart, University of Copenhagen Faculty of Health and Medical Sciences, University of Oulu, Diabetes, Safety, Copenhagen, Dietary supplement, Pharmaceutical industry, Medical device, Nicotinamide riboside, Cardiology

On June 13th, ChromaDex Corp. (NASDAQ:CDXC), a global authority on nicotinamide adenine dinucleotide (NAD+) research and healthy aging, celebrated the 10th anniversary of its award-winning ChromaDex External Research Program (CERP™).

Key Points: 
  • On June 13th, ChromaDex Corp. (NASDAQ:CDXC), a global authority on nicotinamide adenine dinucleotide (NAD+) research and healthy aging, celebrated the 10th anniversary of its award-winning ChromaDex External Research Program (CERP™).
  • On behalf of the ChromaDex family, we are thrilled to commemorate our ChromaDex External Research Program as it celebrates a decade of setting the industry standard for excellence in collaborative research,” said Rob Fried, the CEO of ChromaDex.
  • This approach fosters great trust in the research, as often there is skepticism around industry-funded research in the dietary supplement industry.
  • Today, this unique, industry-leading program has research agreements with over 200 institutions in 31 countries, representing over $95 million in estimated total research value.

Cytovation Strengthens its Board of Directors for Next Phase of Development

Retrieved on: 
Thursday, September 15, 2022
Norwegian Government Security and Service Organisation, CFO, Biomedical Research, Company, Haukeland University Hospital, New Board, Sandwater, Industry, Patient, Doctor of Philosophy, Board, BMS, Boehringer Ingelheim, Mohn, University, Oslo Stock Exchange, University of Bergen, Pharmaceutical industry, Management, MD, Innovation Norway

Current CEO of Mohn Drilling, Mohn combines over 16 years of industry experience with an extensive scientific background in biomedical research.

Key Points: 
  • Current CEO of Mohn Drilling, Mohn combines over 16 years of industry experience with an extensive scientific background in biomedical research.
  • Representing Canica AS, a large, privately owned investment company operating out of Norway and Switzerland, which co-led the Series A round together with Sandwater, Cytovation has welcomed yvind Kongstun Arnesen to the Board.
  • Stein Christian Mohn, Chair of Cytovation, commented: "I am delighted to be taking on the role of Chairperson at Cytovation, having witnessed the company's impressive progress during my time on the Board.
  • I would like to welcome our new board members, each of whom brings considerable experience to Cytovation as we move into the next phase of development.